NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research note issued on Saturday. The brokerage set a “hold” rating on the stock.

NovaBay Pharmaceuticals Stock Down 0.7 %

NYSE:NBY opened at $0.69 on Friday. NovaBay Pharmaceuticals has a 12-month low of $0.36 and a 12-month high of $12.22. The firm has a market capitalization of $3.39 million, a PE ratio of -0.01 and a beta of 0.73. The firm has a 50-day moving average price of $0.62 and a 200 day moving average price of $1.67.

NovaBay Pharmaceuticals (NYSE:NBY) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($1.37) earnings per share (EPS) for the quarter. The business had revenue of $2.40 million during the quarter. NovaBay Pharmaceuticals had a negative return on equity of 744.33% and a negative net margin of 102.72%. On average, research analysts expect that NovaBay Pharmaceuticals will post -1.41 EPS for the current year.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.